文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

围手术期特瑞普利单抗联合化疗用于可切除非小细胞肺癌患者:Neotorch随机临床试验

Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial.
PubMed 文献 · JAMA · 2024-01-01

这项随机临床试验在中国50家医院纳入II期或III期可切除非小细胞肺癌患者,按1:1随机接受特瑞普利单抗或安慰剂联合铂类化疗。 interim分析显示,特瑞普利单抗组无事件生存期显著优于安慰剂组,主要病理缓解率和病理完全缓解率显著提高,安全性总体可控。

要点

  • 特瑞普利单抗组无事件生存期未达到中位值,安慰剂组为15.1个月(HR 0.40,95%CI 0.28-0.57,P<.001)。
  • 特瑞普利单抗组主要病理缓解率48.5%,安慰剂组8.4%(组间差40.2%,95%CI 32.2%-48.1%,P<.001)。
  • 特瑞普利单抗组免疫相关不良事件更常见,3级及以上不良事件、致死性不良事件和导致停药的不良事件两组相当。

核心结论

  • 在可切除III期非小细胞肺癌患者中,围手术期化疗基础上加用特瑞普利单抗显著改善无事件生存期,且安全性总体可控。

研究设计与样本

  • 随机临床试验,在中国50家医院纳入II期或III期可切除非小细胞肺癌患者(非鳞癌无EGFR或ALK变异),入组时间2020年3月12日至2023年6月19日,本次 interim分析数据截止2022年11月30日。
  • 共随机501例患者,其中404例为III期NSCLC(特瑞普利单抗+化疗组202例,安慰剂+化疗组202例),97例II期NSCLC被排除出本次 interim分析。
  • 患者按1:1随机接受特瑞普利单抗240 mg或安慰剂每3周一次联合铂类化疗,术前3周期、术后1周期,随后特瑞普利单抗240 mg或安慰剂每3周一次最多13周期。

主要发现

  • 中位年龄62岁(IQR 56-65岁),92%为男性,中位随访18.3个月(IQR 12.7-22.5个月)。
  • 无事件生存期:特瑞普利单抗组中位值不可估计(95%CI 24.4个月-不可估计),安慰剂组15.1个月(95%CI 10.6-21.9个月),HR 0.40(95%CI 0.28-0.57),P<.001。
  • 主要病理缓解率:特瑞普利单抗组48.5%(95%CI 41.4%-55.6%),安慰剂组8.4%(95%CI 5.0%-13.1%),组间差40.2%(95%CI 32.2%-48.1%),P<.001。
  • 病理完全缓解率:特瑞普利单抗组24.8%(95%CI 19.0%-31.3%),安慰剂组1.0%(95%CI 0.1%-3.5%),组间差23.7%(95%CI 17.6%-29.8%)。
  • 免疫相关不良事件在特瑞普利单抗组更常见,未发现意料之外的治疗相关毒性效应,3级及以上不良事件、致死性不良事件和导致停药的不良事件两组相当。

关键数值与推荐

  • 无事件生存期HR 0.40(95%CI 0.28-0.57),P<.001,特瑞普利单抗组优于安慰剂组。
  • 主要病理缓解率组间差40.2%(95%CI 32.2%-48.1%),P<.001,特瑞普利单抗组48.5% vs 安慰剂组8.4%。
  • 病理完全缓解率组间差23.7%(95%CI 17.6%-29.8%),特瑞普利单抗组24.8% vs 安慰剂组1.0%。

临床怎么用

  • 对于可切除III期非小细胞肺癌患者,围手术期化疗联合特瑞普利单抗较单纯化疗改善无事件生存期和主要病理缓解率。
  • 特瑞普利单抗组免疫相关不良事件更常见,但3级及以上不良事件、致死性不良事件和导致停药的不良事件两组相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Adjuvant and neoadjuvant immunotherapy have improved clinical outcomes for patients with early-stage non-small cell lung cancer (NSCLC). However, the optimal combination of checkpoint inhibition with chemotherapy remains unknown. OBJECTIVE: To determine whether toripalimab in combination with platinum-based chemotherapy will improve event-free survival and major pathological response in patients with stage II or III resectable NSCLC compared with chemotherapy alone. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial enrolled patients with stage II or III resectable NSCLC (without EGFR or ALK alterations for nonsquamous NSCLC) from March 12, 2020, to June 19, 2023, at 50 participating hospitals in China. The data cutoff date for this interim analysis was November 30, 2022. INTERVENTIONS: Patients were randomized in a 1:1 ratio to receive 240 mg of toripalimab or placebo once every 3 weeks combined with platinum-based chemotherapy for 3 cycles before surgery and 1 cycle after surgery, followed by toripalimab only (240 mg) or placebo once every 3 weeks for up to 13 cycles. MAIN OUTCOMES AND MEASURES: The primary outcomes were event-free survival (assessed by the investigators) and the major pathological response rate (assessed by blinded, independent pathological review). The secondary outcomes included the pathological complete response rate (assessed by blinded, independent pathological review) and adverse events. RESULTS: Of the 501 patients randomized, 404 had stage III NSCLC (202 in the toripalimab + chemotherapy group and 202 in the placebo + chemotherapy group) and 97 had stage II NSCLC and were excluded from this interim analysis. The median age was 62 years (IQR, 56-65 years), 92% of patients were male, and the median follow-up was 18.3 months (IQR, 12.7-22.5 months). For the primary outcome of event-free survival, the median length was not estimable (95% CI, 24.4 months-not estimable) in the toripalimab group compared with 15.1 months (95% CI, 10.6-21.9 months) in the placebo group (hazard ratio, 0.40 [95% CI, 0.28-0.57], P < .001). The major pathological response rate (another primary outcome) was 48.5% (95% CI, 41.4%-55.6%) in the toripalimab group compared with 8.4% (95% CI, 5.0%-13.1%) in the placebo group (between-group difference, 40.2% [95% CI, 32.2%-48.1%], P < .001). The pathological complete response rate (secondary outcome) was 24.8% (95% CI, 19.0%-31.3%) in the toripalimab group compared with 1.0% (95% CI, 0.1%-3.5%) in the placebo group (between-group difference, 23.7% [95% CI, 17.6%-29.8%]). The incidence of immune-related adverse events occurred more frequently in the toripalimab group. No unexpected treatment-related toxic effects were identified. The incidence of grade 3 or higher adverse events, fatal adverse events, and adverse events leading to discontinuation of treatment were comparable between the groups. CONCLUSIONS AND RELEVANCE: The addition of toripalimab to perioperative chemotherapy led to a significant improvement in event-free survival for patients with resectable stage III NSCLC and this treatment strategy had a manageable safety profile. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04158440.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Lu S, Zhang W, Wu L, et al. Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial. JAMA. 2024. PMID: 38227033. doi:10.1001/jama.2023.24735

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。